PTCT:NASDAQ
PTC Therapeutics, Inc.
$63.46
arrow_downward
-1.04%(-0.67) 1D
$63.46
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 2, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
$64.81
High
$65.40
Low
$62.80
Mkt. cap
5.30B
Avg. vol.
1.09M
Volume
892.73K
52-wk high
$90.86
52-wk low
$61.23
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
Open
$64.81
High
$65.40
Low
$62.80
Mkt. cap
5.30B
Avg. vol.
1.09M
Volume
892.73K
52-wk high
$90.86
52-wk low
$61.23
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
News stories
From web sources and news partners
Intellia Therapeutics
·
46 minutes ago
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
·
33 minutes ago
NeuroSense Provides Update on Nasdaq Listing Compliance
Yahoo Finance UK
·
47 minutes ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investor's Business Daily
·
14 minutes ago
Dow Jones Futures: Nasdaq Hits High As Nvidia, SpaceX, Bloom Energy Flash Buy Signals. What To Do Now.
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com